Lantheus Holdings, Inc. reported second-quarter 2026 results with revenue of $388.18M, up 2.7% from $378.05M a year earlier, net income of $75.03M (down from $78.76M), and diluted EPS of $1.11 compared with $1.12 in the year‑ago quarter — a largely flat per‑share outcome. The quarter reflected growth in PET radiodiagnostics volumes and results from recent acquisitions alongside the completed divestiture of the SPECT business.

Financial Highlights

  • Revenue was $388.18M for Q2 2026, compared with $378.05M in the year‑ago quarter; YoY change 2.7%.
  • Net income was $75.03M for Q2 2026, compared with $78.76M in the year‑ago quarter; YoY change (4.7%).
  • Diluted earnings per share was $1.11 for Q2 2026, compared with $1.12 in the year‑ago quarter; YoY change (0.9%).

Business Highlights

  • Revenue growth was driven by Neuraceq sales following acquisition and higher volumes of DEFINITY and PYLARIFY.
  • Company reorganized reporting after the SPECT business divestiture, shifting to Oncology, Neurology, Cardiology and Strategic Revenue and focusing on PET radiodiagnostics.
  • Regulatory and commercial progress: FDA approved PYLARIFY TruVu in March 2026 with an HCPCS code effective Oct. 1, 2026; commercial rollout begins in Q4 2026.
  • Completed acquisitions of Lantheus Biosciences and Evergreen; sold the SPECT business effective Jan. 1, 2026; advanced CDMO and PMF network builds.
  • R&D focus includes advancing MK-6240 NDA with a PDUFA date of Aug. 13, 2026, addressing manufacturing issues for LNTH-2501 following a CRL, and initiating registrational plans for RM2.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.